Hear ye: New eardrop packs combo punch

October 6, 2003

Clinicians will soon be able to offer the parents of children with common ear infections the first ototopical therapy that combines the antibacterial activity of ciprofloxacin and the antiinflammatory properties of dexamethasone. The FDA recently approved ciprofloxacin, 0.3% and dexamethasone, 0.1% (Ciprodex, Alcon) sterile otic suspension for the treatment of acute otitis media due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa in children age six months and older with tympanostomy tubes. Ciprodex was also approved for the treatment of acute otitis externa due to Staphylococcus aureus and Pseudomonas aeruginosa in children age six months and older, adults, and older persons.